Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

EMBO Molecular Medicine

Volumn 7, Issue 8, 2015, Pages 1034-1047

  Olsson, Eleonor ^a,b   Winter, Christof ^a,b   George, Anthony ^a,b   Chen, Yilun ^a,b   Howlin, Jillian ^a,b   Tang, Man Hung Eric ^a,b   Dahlgren, Malin ^a,b   Schulz, Ralph ^a,b   Grabau, Dorthe ^c   van Westen, Danielle ^c   Fernö, Mårten ^a,b   Ingvar, Christian ^c   Rose, Carsten ^b   Bendahl, Pär Ola ^a,b   Rydén, Lisa ^b,c   Borg, Åke ^a,b   Gruvberger Saal, Sofia K ^a,b   Jernström, Helena ^a,b   Saal, Lao H ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast carcinoma; Circulating tumor DNA; Early detection; Liquid biopsy; Metastasis

Indexed keywords

ANASTROZOLE; CIRCULATING TUMOR DNA; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; ERIBULIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILATERAL CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHROMOSOME 10Q; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 4Q; CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DROPLET DIGITAL POLYMERASE CHAIN REACTION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WHOLE GENOME SEQUENCING; BLOOD; BREAST TUMOR; COMPLICATION; FEMALE; LONGITUDINAL STUDY; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; DNA; FEMALE; HUMANS; LONGITUDINAL STUDIES; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84938414305     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404913     Document Type: Article

References (40)

1. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409
2. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky D, Wong HY, Valda Toro P, Cidado J, Blair BG et al (2014) Detection of cancer DNA in plasma of early stage breast cancer patients. Clin Cancer Res 20: 2643-2650
3. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6: 224ra224
4. Borgquist S, Hjertberg M, Henningson M, Ingvar C, Rose C, Jernstrom H (2013) Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms. Breast Cancer Res Treat 137: 849-862
5. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70
6. Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, Buchholz TA, Giordano SH (2012) Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev 21: 800-809
7. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368: 1199-1209
8. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540
9. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990
10. Dolken G (2001) Detection of minimal residual disease. Adv Cancer Res 82: 133-185
11. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
12. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC et al (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486: 353-360
13. Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80: 27-38
14. Heinze G (2006) A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med 25: 4216-4226
15. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC et al (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83: 8604-8610
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90
17. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA et al (2010) Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 12: R42
18. Jung K, Fleischhacker M, Rabien A (2010) Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411: 1611-1624
19. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31: 961-965
20. Kosmidis I. (2013) brglm: Bias reduction in binary-response Generalized Linear Models
21. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639-1645
22. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM et al (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2: 20ra14
23. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B et al (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4: 162ra154
24. Lippman M, Osborne CK (2013) Circulating tumor DNA-ready for prime time? N Engl J Med 368: 1249-1250
25. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13: 688-695
26. McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hamalainen E, Stebbings LA, Andersson LC, Flanagan AM et al (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosom Cancer 49: 1062-1069
27. McDermott U, Downing JR, Stratton MR (2011) Genomics and the continuum of cancer care. N Engl J Med 364: 340-350
28. Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11: 685-696
29. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536
30. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108-112
31. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20: 548-554
32. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149: 979-993
33. Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106: dju066
34. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J et al (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813
35. Sing T, Sander O, Beerenwinkel N, Lengauer T (2005) ROCR: visualizing classifier performance in R. Bioinformatics 21: 3940-3941
36. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ et al (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010
37. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404
38. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46: 318-322
39. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ et al (2013) Breast cancer, version 3.2013. J Natl Compr Canc Netw 11: 753-761
40. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076-2084